Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. ARCT has been the topic of a number of other reports. BTIG Research began coverage on shares of Arcturus Therapeutics in a research note on Tuesday, January 28th. They issued a […]
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. ARCT has been the topic of a number of other reports. BTIG Research began coverage on shares of Arcturus Therapeutics in a research note on Tuesday, January 28th. They issued a […]
